[go: up one dir, main page]

MX2023010238A - Métodos para tratar trastornos de glóbulos rojos. - Google Patents

Métodos para tratar trastornos de glóbulos rojos.

Info

Publication number
MX2023010238A
MX2023010238A MX2023010238A MX2023010238A MX2023010238A MX 2023010238 A MX2023010238 A MX 2023010238A MX 2023010238 A MX2023010238 A MX 2023010238A MX 2023010238 A MX2023010238 A MX 2023010238A MX 2023010238 A MX2023010238 A MX 2023010238A
Authority
MX
Mexico
Prior art keywords
methods
red blood
blood cell
cell disorders
treating red
Prior art date
Application number
MX2023010238A
Other languages
English (en)
Inventor
Laurie H Glimcher
Mahesh Raundhal
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of MX2023010238A publication Critical patent/MX2023010238A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere, en parte, a métodos para tratar trastornos de glóbulos rojos, tales como un MDS y/o una anemia, mediante la regulación descendente de la señalización de IL-22.
MX2023010238A 2021-03-02 2022-03-02 Métodos para tratar trastornos de glóbulos rojos. MX2023010238A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163155430P 2021-03-02 2021-03-02
PCT/US2022/018538 WO2022187374A1 (en) 2021-03-02 2022-03-02 Methods of treating red blood cell disorders

Publications (1)

Publication Number Publication Date
MX2023010238A true MX2023010238A (es) 2023-12-05

Family

ID=80786757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010238A MX2023010238A (es) 2021-03-02 2022-03-02 Métodos para tratar trastornos de glóbulos rojos.

Country Status (10)

Country Link
US (1) US20240083995A1 (es)
EP (1) EP4301777A1 (es)
JP (1) JP2024509530A (es)
KR (1) KR20230165212A (es)
CN (1) CN117425674A (es)
AU (1) AU2022229805A1 (es)
CA (1) CA3212132A1 (es)
IL (1) IL305575A (es)
MX (1) MX2023010238A (es)
WO (1) WO2022187374A1 (es)

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
CH223191A (de) 1942-05-28 1942-08-31 Ramel Otto Vorrichtung zum Betätigen der Bremsen an Fahrrädern.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
US5255387A (en) 1990-04-27 1993-10-19 International Business Machines Corporation Method and apparatus for concurrency control of shared data updates and queries
EP0562047A4 (en) 1990-12-06 1995-11-02 Affymax Tech Nv Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2131543C (en) 1992-03-04 2002-09-17 Daniel Pinkel Comparative genomic hybridization
US5856097A (en) 1992-03-04 1999-01-05 The Regents Of The University Of California Comparative genomic hybridization (CGH)
KR100249110B1 (ko) 1992-05-06 2000-04-01 다니엘 엘. 캐시앙 핵산 서열 증폭 방법, 이에 이용되는 조성물 및 키트
WO1994002610A1 (en) 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
EP0679196B1 (en) 1993-01-07 2004-05-26 Sequenom, Inc. Dna sequencing by mass spectrometry
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
DE4344726C2 (de) 1993-12-27 1997-09-25 Deutsches Krebsforsch Verfahren zum Nachweis von nicht balanciertem genetischen Material einer Spezies oder zum Nachweis der Genexpression in Zellen einer Spezies
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
CA2255430C (en) 1998-12-10 2003-08-26 P. Wedge Co. Ltd. A swivel device for a windcone tower assembly
US7045498B2 (en) * 2000-08-08 2006-05-16 Zymogenetics, Inc. Soluble Zcytor11 cytokine receptors
AU2001286171B2 (en) 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
EP1425694A2 (en) 2001-08-03 2004-06-09 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
WO2003089569A2 (en) * 2001-11-06 2003-10-30 Eli Lilly And Company Use of il-19, il-22 and il-24 to treat hematopoietic disorders
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
US7537761B2 (en) * 2004-10-22 2009-05-26 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
GB201508841D0 (en) * 2015-05-22 2015-07-01 Isis Innovation Treatment
CN110157733A (zh) * 2018-02-11 2019-08-23 四川大学 重组mIL-22BP载体、脂质体复合物及其制备方法和用途

Also Published As

Publication number Publication date
CA3212132A1 (en) 2022-09-09
KR20230165212A (ko) 2023-12-05
AU2022229805A1 (en) 2023-09-21
JP2024509530A (ja) 2024-03-04
CN117425674A (zh) 2024-01-19
IL305575A (en) 2023-10-01
US20240083995A1 (en) 2024-03-14
EP4301777A1 (en) 2024-01-10
WO2022187374A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
ZA202303412B (en) Anti-galectin-9 antibodies and uses thereof
PH12018500663A1 (en) Antigen-binding proteins that activate the leptin receptor
MX2020012416A (es) Anticuerpos dirigidos contra il-33 y sus usos.
SA521422031B1 (ar) مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين
MA39250B1 (fr) Protéines hybrides de l'interleukine-2 et leurs utilisations
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
EA201992546A1 (ru) Средства на основе антител к cd33
PH12016500943A1 (en) Aplnr modulatros and uses thereof
PH12018502035A1 (en) Protease-activated t cell bispecific molecules
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
TN2016000553A1 (en) Methods and compositions for treating ulcers
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
MX2014014951A (es) Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
EA201491574A1 (ru) Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car
MX2020006654A (es) Métodos intraductales de tratamiento de trastornos de mama.
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
MX2021006980A (es) Anticuerpos anti-il-27 y usos de estos.
NZ767839A (en) Anti-il-27 antibodies and uses thereof
MX2024002281A (es) Anticuerpos anti-cd161 y usos de los mismos.
MY194041A (en) Anti-tnfalpha-antibodies and functional fragments thereof
WO2019241730A3 (en) Increasing immune activity through modulation of postcellular signaling factors
ZA202006216B (en) Antibodies targeting glycoprotein vi
WO2016164468A3 (en) Human monoclonal autoantibodies to adamts13 and uses thereof
ZA202306764B (en) Antibody targeting cd47 and application thereof
MX2023010238A (es) Métodos para tratar trastornos de glóbulos rojos.